Responses
Regular and Young Investigator Award Abstracts
Clinical Trial In Progress
751 Monotherapy results from an ongoing phase 1a dose escalation study of NDI-101150, a highly selective oral hematopoietic progenitor kinase 1 (HPK1) inhibitor
Compose a Response to This Article
Other responses
No responses have been published for this article.
